Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lymphoma, Large B-Cell, Diffuse 3Multiple Myeloma 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma, B-Cell 2Recurrence 1Multi-centric Castleman's Disease 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immunoglobulin Light-chain Amyloidosis 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1Amyloidosis 1

Interventions

Carboplatin 330Pemetrexed 266Cisplatin 234Docetaxel 195Paclitaxel 182Radiotherapy 181Erlotinib Hydrochloride 153pembrolizumab 147Gemcitabine 147Bevacizumab 125Drug Therapy 121Radiosurgery 115Nivolumab 112osimertinib 92durvalumab 88Gefitinib 67atezolizumab 63Vinorelbine 63Surgical Procedures, Operative 62Magnetic Resonance Spectroscopy 54anlotinib 42Immunotherapy 42Taxes 39Blood Specimen Collection 39Ipilimumab 38130-nm albumin-bound paclitaxel 38Specimen Handling 36Immune Checkpoint Inhibitors 35Radiation 34Albumin-Bound Paclitaxel 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Non-Small-Cell Lung × Hyaluronoglucosaminidase × Clear all
NCT05340309 2026-01-29

Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer

University of Southern California

Phase 2 Active not recruiting
5 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡